|
CA2853829C
(en)
|
2011-07-22 |
2023-09-26 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
JP6219832B2
(en)
|
2011-10-17 |
2017-10-25 |
マサチューセッツ インスティテュート オブ テクノロジー |
Intracellular delivery
|
|
EP2841572B1
(en)
|
2012-04-27 |
2019-06-19 |
Duke University |
Genetic correction of mutated genes
|
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
|
KR102386122B1
(en)
|
2013-08-16 |
2022-04-14 |
메사추세츠 인스티튜트 오브 테크놀로지 |
Selective delivery of material to cells
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9737604B2
(en)
|
2013-09-06 |
2017-08-22 |
President And Fellows Of Harvard College |
Use of cationic lipids to deliver CAS9
|
|
US9340800B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
Extended DNA-sensing GRNAS
|
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
|
LT3066201T
(en)
|
2013-11-07 |
2018-08-10 |
Editas Medicine, Inc. |
Crispr-related methods and compositions with governing grnas
|
|
US20150166982A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting pi3k point mutations
|
|
CA2954414A1
(en)
|
2014-07-15 |
2016-01-21 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
|
WO2016022363A2
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
RU2020139190A
(en)
|
2014-10-31 |
2021-01-26 |
Массачусетс Инститьют Оф Текнолоджи |
DELIVERY OF BIOMOLECULES INTO THE CELLS OF THE IMMUNE SYSTEM
|
|
EP3215168B1
(en)
*
|
2014-10-31 |
2023-08-02 |
The Trustees of the University of Pennsylvania |
Altering gene expression in modified t cells and uses thereof
|
|
CN107002089B
(en)
|
2014-11-14 |
2021-09-07 |
麻省理工学院 |
Disruption and field-effected delivery of compounds and compositions into cells
|
|
EP3230451B1
(en)
|
2014-12-12 |
2021-04-07 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
WO2016094880A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
|
AU2015369725A1
(en)
|
2014-12-24 |
2017-06-29 |
Massachusetts Institute Of Technology |
CRISPR having or associated with destabilization domains
|
|
CN107250373A
(en)
|
2015-01-12 |
2017-10-13 |
麻省理工学院 |
Gene editing by microfluidic delivery
|
|
US20180112213A1
(en)
*
|
2015-03-25 |
2018-04-26 |
Editas Medicine, Inc. |
Crispr/cas-related methods, compositions and components
|
|
EP4269601A3
(en)
*
|
2015-03-27 |
2024-01-10 |
President and Fellows of Harvard College |
Modified t cells and methods of making and using the same
|
|
EP3294342A4
(en)
|
2015-05-08 |
2018-11-07 |
President and Fellows of Harvard College |
Universal donor stem cells and related methods
|
|
JP7030522B2
(en)
*
|
2015-05-11 |
2022-03-07 |
エディタス・メディシン、インコーポレイテッド |
Optimized CRISPR / CAS9 system and method for gene editing in stem cells
|
|
EP3294888A1
(en)
*
|
2015-05-11 |
2018-03-21 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating hiv infection and aids
|
|
EP3303586A1
(en)
|
2015-05-29 |
2018-04-11 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
|
WO2016201047A1
(en)
|
2015-06-09 |
2016-12-15 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for improving transplantation
|
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
CA2988996A1
(en)
|
2015-07-09 |
2017-01-12 |
Massachusetts Institute Of Technology |
Delivery of materials to anucleate cells
|
|
MA42895A
(en)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
|
|
US10906951B2
(en)
|
2015-07-29 |
2021-02-02 |
Onk Therapeutics Limited |
Modified natural killer cells and natural killer cell lines having increased cytotoxicity
|
|
DK3421590T3
(en)
|
2015-07-29 |
2021-10-04 |
Onk Therapeutics Ltd |
MODIFIED NATURAL KILLER CELLS AND NATURAL KILLER CELL LINES WITH INCREASED CYTOTOXICITY
|
|
EP3328399B1
(en)
*
|
2015-07-31 |
2023-12-27 |
Regents of the University of Minnesota |
Modified cells and methods of therapy
|
|
US11613759B2
(en)
|
2015-09-04 |
2023-03-28 |
Sqz Biotechnologies Company |
Intracellular delivery of biomolecules to cells comprising a cell wall
|
|
US11970710B2
(en)
|
2015-10-13 |
2024-04-30 |
Duke University |
Genome engineering with Type I CRISPR systems in eukaryotic cells
|
|
JP7067793B2
(en)
|
2015-10-23 |
2022-05-16 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Nucleobase editing factors and their use
|
|
JP7408284B2
(en)
|
2015-10-30 |
2024-01-05 |
エディタス・メディシン、インコーポレイテッド |
CRISPR/CAS-related methods and compositions for treating herpes simplex virus
|
|
AU2016362129A1
(en)
*
|
2015-12-04 |
2018-06-14 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
CN116218916A
(en)
*
|
2016-01-12 |
2023-06-06 |
Sqz生物技术公司 |
Intracellular delivery of complexes
|
|
US11530253B2
(en)
|
2016-02-25 |
2022-12-20 |
The Children's Medical Center Corporation |
Customized class switch of immunoglobulin genes in lymphoma and hybridoma by CRISPR/CAS9 technology
|
|
CN109312340A
(en)
*
|
2016-03-04 |
2019-02-05 |
爱迪塔斯医药公司 |
CRISPR-CPF1 correlation technique, composition and component for immunotherapy for cancer
|
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
|
JP2019512271A
(en)
*
|
2016-03-21 |
2019-05-16 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
T cell exhaustion state specific gene expression regulator and use thereof
|
|
BR112018071439A2
(en)
*
|
2016-04-22 |
2019-03-19 |
Intellia Therapeutics, Inc. |
compositions and methods for treating diseases associated with three nucleotide repeats at transcription factor four
|
|
CN107304434A
(en)
*
|
2016-04-25 |
2017-10-31 |
上海宇玫博生物科技有限公司 |
A kind of difunctional novel carriers of immune cell therapy
|
|
MX2018013445A
(en)
|
2016-05-06 |
2019-09-09 |
Juno Therapeutics Inc |
Genetically engineered cells and methods of making the same.
|
|
CA3022319A1
(en)
*
|
2016-05-06 |
2017-11-09 |
Tod M. Woolf |
Improved methods for genome editing with and without programmable nucleases
|
|
US10912287B2
(en)
|
2016-06-28 |
2021-02-09 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd |
Genetically modified mice expressing humanized PD-1
|
|
WO2018027036A1
(en)
*
|
2016-08-03 |
2018-02-08 |
Dipersio John F |
Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
|
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
|
KR102547316B1
(en)
|
2016-08-03 |
2023-06-23 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
Adenosine nucleobase editing agents and uses thereof
|
|
CA3033327A1
(en)
|
2016-08-09 |
2018-02-15 |
President And Fellows Of Harvard College |
Programmable cas9-recombinase fusion proteins and uses thereof
|
|
JP2019528284A
(en)
|
2016-08-17 |
2019-10-10 |
ファクター バイオサイエンス インコーポレイテッド |
Nucleic acid product and method of administration thereof
|
|
WO2018035388A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
|
MX2019003768A
(en)
|
2016-10-03 |
2019-06-24 |
Juno Therapeutics Inc |
Hpv-specific binding molecules.
|
|
US11896615B2
(en)
|
2016-10-13 |
2024-02-13 |
Juno Therapeutics, Inc. |
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
|
|
WO2018071868A1
(en)
|
2016-10-14 |
2018-04-19 |
President And Fellows Of Harvard College |
Aav delivery of nucleobase editors
|
|
GB2605883B
(en)
|
2016-10-18 |
2023-03-15 |
Univ Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
|
JP2019536447A
(en)
*
|
2016-10-27 |
2019-12-19 |
インティマ バイオサイエンス， インコーポレイテッド |
Viral method of T cell therapy
|
|
US11332713B2
(en)
|
2016-11-16 |
2022-05-17 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
|
RU2019119833A
(en)
|
2016-11-28 |
2020-12-29 |
Нападжен Фарма, Инк. |
CHEMICALLY MODIFIED miRNA
|
|
BR112019011207A2
(en)
|
2016-12-05 |
2019-10-08 |
Juno Therapeutics Inc |
modified cell production for adoptive cell therapy
|
|
CN118546256A
(en)
|
2016-12-13 |
2024-08-27 |
西雅图儿童医院（Dba西雅图儿童研究所） |
Method for exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
AU2017386790A1
(en)
*
|
2016-12-30 |
2019-07-18 |
Celularity Inc. |
Genetically modified natural killer cells
|
|
EP3573657A4
(en)
*
|
2017-01-29 |
2021-04-14 |
Zequn Tang |
Methods of immune modulation against foreign and/or auto antigens
|
|
TW201839136A
(en)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
Compositions and methods for the treatment of hemoglobinopathies
|
|
US10828330B2
(en)
*
|
2017-02-22 |
2020-11-10 |
IO Bioscience, Inc. |
Nucleic acid constructs comprising gene editing multi-sites and uses thereof
|
|
WO2018165504A1
(en)
|
2017-03-09 |
2018-09-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
|
US11542496B2
(en)
|
2017-03-10 |
2023-01-03 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
|
US11851659B2
(en)
*
|
2017-03-22 |
2023-12-26 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
SG11201908658TA
(en)
|
2017-03-23 |
2019-10-30 |
Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
US10934336B2
(en)
|
2017-04-13 |
2021-03-02 |
The Trustees Of The University Of Pennsylvania |
Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy
|
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
CA3062506A1
(en)
|
2017-05-12 |
2019-05-23 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
US10428319B2
(en)
|
2017-06-09 |
2019-10-01 |
Editas Medicine, Inc. |
Engineered Cas9 nucleases
|
|
CN111344020A
(en)
|
2017-06-15 |
2020-06-26 |
加利福尼亚大学董事会 |
Targeted non-viral DNA insertion
|
|
US20200181608A1
(en)
*
|
2017-06-20 |
2020-06-11 |
Jiangsu Hengrui Medicine Co., Ltd. |
METHOD FOR KNOCKING OUT TARGET GENE IN T CELL IN VITRO AND crRNA USED IN THE METHOD
|
|
SG10201705285SA
(en)
*
|
2017-06-27 |
2019-01-30 |
Agency Science Tech & Res |
Antisense oligonucleotides
|
|
JP2020530307A
(en)
|
2017-06-30 |
2020-10-22 |
インティマ・バイオサイエンス，インコーポレーテッド |
Adeno-associated virus vector for gene therapy
|
|
WO2019003193A1
(en)
*
|
2017-06-30 |
2019-01-03 |
Novartis Ag |
Methods for the treatment of disease with gene editing systems
|
|
CN111801345A
(en)
|
2017-07-28 |
2020-10-20 |
哈佛大学的校长及成员们 |
Methods and compositions using an evolved base editor for Phage Assisted Continuous Evolution (PACE)
|
|
EP3676376A2
(en)
|
2017-08-30 |
2020-07-08 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
|
CN111148533A
(en)
|
2017-09-19 |
2020-05-12 |
麻省理工学院 |
Compositions for chimeric antigen receptor T cell therapy and uses thereof
|
|
EP4215543A3
(en)
|
2017-10-03 |
2023-10-11 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
|
WO2019072241A1
(en)
|
2017-10-13 |
2019-04-18 |
Beijing Biocytogen Co., Ltd |
Genetically modified non-human animal with human or chimeric pd-1
|
|
CN111757937A
(en)
|
2017-10-16 |
2020-10-09 |
布罗德研究所股份有限公司 |
Use of adenosine base editor
|
|
WO2019084552A1
(en)
|
2017-10-27 |
2019-05-02 |
The Regents Of The University Of California |
Targeted replacement of endogenous t cell receptors
|
|
WO2019089982A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
|
JP2021502077A
(en)
*
|
2017-11-06 |
2021-01-28 |
エディタス・メディシン，インコーポレイテッド |
Methods, compositions and components for CRISPR-CAS9 editing of CBLB on T cells for immunotherapy
|
|
US20210187018A1
(en)
*
|
2017-12-07 |
2021-06-24 |
Flagship Pioneering Innovations V, Inc. |
Cytobiologics and therapeutic uses thereof
|
|
WO2019118508A1
(en)
|
2017-12-12 |
2019-06-20 |
The Trustees Of The University Of Pennsylvania |
Genetically modified immune cells targeting ny-eso-1 and methods of use thereof
|
|
WO2019118793A2
(en)
*
|
2017-12-14 |
2019-06-20 |
Ezy Biotech Llc |
Subject-specific tumor inhibiting cells and the use thereof
|
|
EP3765615B1
(en)
|
2018-03-14 |
2023-06-28 |
Arbor Biotechnologies, Inc. |
Novel crispr dna targeting enzymes and systems
|
|
US20190284553A1
(en)
|
2018-03-15 |
2019-09-19 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
|
CN112040986A
(en)
|
2018-03-15 |
2020-12-04 |
Ksq治疗公司 |
Gene regulatory compositions and methods for improved immunotherapy
|
|
US20210017249A1
(en)
|
2018-04-05 |
2021-01-21 |
Juno Therapeutics, Inc. |
Methods of producing cells expressing a recombinant receptor and related compositions
|
|
SG11202009446TA
(en)
|
2018-04-05 |
2020-10-29 |
Juno Therapeutics Inc |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
|
WO2019195486A1
(en)
|
2018-04-05 |
2019-10-10 |
Juno Therapeutics, Inc. |
T cell receptors and engineered cells expressing same
|
|
KR20200120702A
(en)
*
|
2018-04-13 |
2020-10-21 |
시그마-알드리치 컴퍼니., 엘엘씨 |
Modification of immune-related genomic loci using paired CRISPR nickase ribonucleic acid protein
|
|
CN112041436A
(en)
|
2018-04-27 |
2020-12-04 |
西雅图儿童医院（Dba西雅图儿童研究所） |
Rapamycin resistant cells
|
|
SG11202011080QA
(en)
|
2018-05-11 |
2020-12-30 |
Crispr Therapeutics Ag |
Methods and compositions for treating cancer
|
|
DK3806903T5
(en)
|
2018-06-14 |
2024-08-19 |
2Seventy Bio Inc |
CD79A CHIMERIC ANTIGEN RECEPTORS
|
|
CN108866004A
(en)
*
|
2018-06-26 |
2018-11-23 |
奥妙生物技术（广州）有限公司 |
The T cell and its construction method that SHP-1 is knocked out
|
|
US20210317406A1
(en)
*
|
2018-07-09 |
2021-10-14 |
The Regents Of The University Of California |
Gene targets for t-cell-based immunotherapy
|
|
KR20200011899A
(en)
*
|
2018-07-25 |
2020-02-04 |
주식회사 툴젠 |
Genome editing for treating autoimmune disease
|
|
WO2020022803A1
(en)
*
|
2018-07-26 |
2020-01-30 |
주식회사 툴젠 |
Gene editing of anticoagulants
|
|
US20210348177A1
(en)
|
2018-09-05 |
2021-11-11 |
The Regents Of The University Of California |
Generation of heritably gene-edited plants without tissue culture
|
|
WO2020055962A1
(en)
*
|
2018-09-11 |
2020-03-19 |
Board Of Regents, The University Of Texas System |
A genetic mouse model of autoimmune adverse events and immune checkpoint blockade therapy
|
|
WO2020068261A1
(en)
|
2018-09-28 |
2020-04-02 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
WO2020072059A1
(en)
*
|
2018-10-04 |
2020-04-09 |
Bluebird Bio, Inc. |
Cblb endonuclease variants, compositions, and methods of use
|
|
AU2019362879A1
(en)
*
|
2018-10-16 |
2021-05-27 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunotherapy
|
|
MX2021004898A
(en)
*
|
2018-10-29 |
2021-06-18 |
Univ China Agricultural |
Novel crispr/cas12f enzyme and system.
|
|
CN113544266A
(en)
|
2018-12-17 |
2021-10-22 |
博德研究所 |
CRISPR-associated transposase systems and methods of use thereof
|
|
EP3917541A4
(en)
*
|
2019-01-28 |
2022-12-07 |
Bar Ilan University |
Combinations, nanoparticles and methods for controlling natural killer cell activation and function
|
|
WO2020168300A1
(en)
|
2019-02-15 |
2020-08-20 |
Editas Medicine, Inc. |
Modified natural killer (nk) cells for immunotherapy
|
|
CN114127285B
(en)
|
2019-03-19 |
2024-09-10 |
布罗德研究所股份有限公司 |
Methods and compositions for editing nucleotide sequences
|
|
WO2020210724A1
(en)
|
2019-04-10 |
2020-10-15 |
University Of Utah Research Foundation |
Htra1 modulation for treatment of amd
|
|
CN113939319A
(en)
|
2019-04-30 |
2022-01-14 |
克里斯珀医疗股份公司 |
Allogeneic cell therapy of genetically engineered T cells targeting CD19 against B cell malignancies
|
|
AU2020265749A1
(en)
|
2019-05-01 |
2022-01-06 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods
|
|
SG11202111360YA
(en)
|
2019-05-01 |
2021-11-29 |
Juno Therapeutics Inc |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
CA3143248A1
(en)
*
|
2019-06-14 |
2020-12-17 |
2Seventy Bio, Inc. |
Compositions and methods for treating cancer
|
|
JP2022538974A
(en)
|
2019-06-26 |
2022-09-07 |
マサチューセッツ インスチテュート オブ テクノロジー |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
EP4183868A4
(en)
*
|
2020-01-23 |
2024-08-21 |
Kangstem Biotech Co Ltd |
Off-the-shelf stem cells and immune cells, and pharmaceutical composition comprising same
|
|
WO2021183207A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OF NPM1c-POSITIVE CANCER
|
|
WO2021216623A1
(en)
|
2020-04-21 |
2021-10-28 |
Aspen Neuroscience, Inc. |
Gene editing of lrrk2 in stem cells and method of use of cells differentiated therefrom
|
|
WO2021216622A1
(en)
|
2020-04-21 |
2021-10-28 |
Aspen Neuroscience, Inc. |
Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom
|
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
US20210338833A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
|
JP2023525304A
(en)
|
2020-05-08 |
2023-06-15 |
ザ ブロード インスティテュート，インコーポレーテッド |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
|
WO2021231661A2
(en)
|
2020-05-13 |
2021-11-18 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
|
AU2021282578A1
(en)
*
|
2020-06-03 |
2023-02-02 |
Mammoth Biosciences, Inc. |
Programmable nucleases and methods of use
|
|
EP4171616A1
(en)
|
2020-06-26 |
2023-05-03 |
Juno Therapeutics GmbH |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
|
US11332744B1
(en)
|
2020-10-26 |
2022-05-17 |
Arsenal Biosciences, Inc. |
Safe harbor loci
|
|
CN116802203A
(en)
|
2020-11-04 |
2023-09-22 |
朱诺治疗学股份有限公司 |
Cells expressing chimeric receptors from modified constant CD3 immunoglobulin superfamily chain loci, related polynucleotides and methods
|
|
EP4284932A1
(en)
*
|
2021-02-01 |
2023-12-06 |
Epsilen Bio S.r.l. |
Gene silencing
|
|
EP4301755A1
(en)
|
2021-03-03 |
2024-01-10 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and a dgk inhibitor
|
|
CA3208944A1
(en)
|
2021-03-22 |
2022-09-29 |
Edith NALBANDIAN |
Method to assess potency of viral vector particles
|
|
WO2022215982A1
(en)
*
|
2021-04-05 |
2022-10-13 |
주식회사 셀렌진 |
Guide rna complementary to trac gene and use thereof
|
|
WO2022232839A1
(en)
|
2021-04-30 |
2022-11-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for improved production of primary cd34+ cells
|
|
EP4355879A2
(en)
|
2021-06-14 |
2024-04-24 |
Graphite Bio, Inc. |
Methods to genetically engineer hematopoietic stem and progenitor cells for red cell specific expression of therapeutic proteins
|
|
WO2022269393A1
(en)
*
|
2021-06-23 |
2022-12-29 |
Crispr Therapeutics Ag |
Engineered cells with improved protection from natural killer cell killing
|
|
EP4362957A1
(en)
|
2021-07-01 |
2024-05-08 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
|
CA3227105A1
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
EP4377459A2
(en)
|
2021-07-30 |
2024-06-05 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
JP2024537991A
(en)
|
2021-10-14 |
2024-10-18 |
アーセナル バイオサイエンシズ インコーポレイテッド |
Immune cells with co-expressed shRNAs and logic gate systems
|
|
CN118660963A
(en)
|
2021-11-01 |
2024-09-17 |
西格马-奥尔德里奇有限责任公司 |
Electroporation enhancers for CRISPR-CAS systems
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
EP4448775A1
(en)
|
2021-12-17 |
2024-10-23 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
|
TW202342498A
(en)
|
2021-12-17 |
2023-11-01 |
美商薩那生物科技公司 |
Modified paramyxoviridae fusion glycoproteins
|
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023137471A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
|
WO2023137472A2
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023201133A1
(en)
|
2022-04-14 |
2023-10-19 |
Board Of Regents Of The University Of Nebraska |
Cell therapy for alzheimer's disease
|
|
US20230372395A1
(en)
|
2022-05-19 |
2023-11-23 |
Massachusetts Institute Of Technology |
Car cells targeting an inserted ligand
|
|
WO2023250511A2
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
|
TW202426641A
(en)
|
2022-08-19 |
2024-07-01 |
美商圖恩療法股份有限公司 |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
|
WO2024044655A1
(en)
|
2022-08-24 |
2024-02-29 |
Sana Biotechnology, Inc. |
Delivery of heterologous proteins
|
|
WO2024054944A1
(en)
|
2022-09-08 |
2024-03-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
|
WO2024064606A2
(en)
*
|
2022-09-19 |
2024-03-28 |
Emendobio Inc. |
Biallelic knockout of ctla4
|
|
WO2024064838A1
(en)
|
2022-09-21 |
2024-03-28 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
|
WO2024119157A1
(en)
|
2022-12-02 |
2024-06-06 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
WO2024161021A1
(en)
|
2023-02-03 |
2024-08-08 |
Juno Therapeutics Gmbh |
Methods for non-viral manufacturing of engineered immune cells
|
|
WO2024220598A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Lentiviral vectors with two or more genomes
|
|
WO2024220574A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
|
|
WO2024220560A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Engineered protein g fusogens and related lipid particles and methods thereof
|
|
CN116539885B
(en)
*
|
2023-07-06 |
2023-09-29 |
上海秤信生物科技有限公司 |
Tumor autoantigen/antibody combination for early detection of breast cancer and application thereof
|